newsfilter
← Latest News
PR Newswire·

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets th